INTRODUCTION
Erectile dysfunction (ED) is predominantly a vascular disease that affects up to 75% of all men with diabetes. [1] [2] [3] [4] In addition, men with diabetic ED respond poorly to the currently available oral phosphodiesterase-5 (PDE5) inhibitors. [5] [6] [7] The reduced responsiveness to PDE5 inhibitors in men with diabetes may be related to the severity of neuropathy and angiopathy. 8, 9 Therefore, functional therapies for diabetic ED are needed.
During the past decade, a variety of studies have been performed on neurovascular regeneration from damaged erectile tissue. These studies have included the delivery of adipose tissue-derived stem cells (ADSCs), 10, 11 adipose tissue-derived stromal vascular fraction (SVF), 12 vascular endothelial growth factor (VEGF), 13 angiopoietin-1 (Ang1), 14, 15 and hepatocyte growth factor (HGF). 16 However, ED in humans is multifactorial in etiology, and single-candidate protein or cell therapy is still unable to completely resolve both the angiogenesis and neuroregeneration in diabetic ED.
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ORIGINAL ARTICLE
Combination of stromal vascular fraction and Ad-COMP-Ang1 gene therapy improves long-term therapeutic efficacy for diabetes-induced erectile dysfunction
Ad-COMP-Ang1 on angiopathy and neuropathy, which extends the therapy effect on erection, in a mouse model of diabetic ED.
MATERIALS AND METHODS
Isolation of SVF and generation of COMP-Ang1 adenovirus
SVF was isolated as previously reported. 12 Briefly, we isolated SVF from epididymal adipose tissues of 10-week-old C57BL/6J mice. The adipose tissue was incubated in Hanks' balanced salt solution containing 0.2% collagenase type 2 (Sigma-Aldrich, St. Louis, MO, USA) for 60 min at 37°C. After incubation, digestion enzyme activity was neutralized with Dulbecco's modified Eagle's medium (GIBCO, Carlsbad, CA, USA) containing 10% fetal bovine serum. The cell suspension was filtered through 70-µm and 40-µm nylon meshes (Becton Dickinson, Mountain View, CA, USA) and then centrifuged (Thermo Fisher Scientific, Waltham, MA, USA) at 580 g for 4 min at 4°C. The adipose tissue-derived stromal vascular fraction (AD-SVF) pellet was resuspended in sterile phosphate-buffered saline (PBS, GIBCO). Recombinant adenovirus expressing COMP-Ang1 or LacZ was provided by Professor Ji-Kan Ryu at Inha University, and the amplification was performed as previously reported. 14, 23 Briefly, HEK293T cells (purchased from the cell bank of the Chinese Academy of Sciences) were used for COMP-Ang1 gene or bacterial -galactosidase (hereafter LacZ) gene infection.
Animals and treatment
Male 8-week-old C57BL/6J mice were purchased from Pengyue Experimental Animal Breeding Center (Jinan, China) and were randomly grouped in this study. Diabetes was induced in 8-week-old mice by intraperitoneal injections of streptozotocin (50 mg kg −1 , Sigma-Aldrich, St. Louis, MO, USA) for 5 consecutive days as previously described.
14 Eight weeks after diabetes was induced, animals were anesthetized with chloral hydrate (300 mg kg −1 , Sangon Biotech, Shanghai, China) intramuscularly, and the penis was exposed by the use of sterile technique. A 30G insulin syringe (Becton Dickinson) was used to administer repeated injections of PBS (days 3 and 0; 20 µl), Ad-LacZ (1 × 10 8 particles per 20 µl), AD-SVF pellet (1 × 10 5 cells per 20 µl of PBS), Ad-COMP-Ang1 (1 × 10 8 particles per 20 µl), or AD-SVF plus Ad-COMP-Ang1 combination into the midportion of the corpus cavernosum. We evaluated erectile function by electrical stimulation of the cavernous nerve 2 and 4 weeks after treatment, and the penis was then harvested for histological examination. Fasting and postprandial blood glucose levels were determined with an Accu-Check blood glucose meter (ACCU-CHEK Performa; Roche Diagnostics, Shanghai, China) before the mice were sacrificed. All mice were treated in accordance with the guidelines for animal care and use of the National Institutes of Health, and ethical approval was granted by the Binzhou Medical University Animal Ethics Committee, Yantai, China. All other methods were performed in accordance with the relevant guidelines and regulations.
Measurement of erectile function
The mice in each group (n = 5) were anesthetized with chloral hydrate (300 mg kg −1 , Sangon Biotech) intramuscularly. Bipolar platinum wire electrodes (BIOPAC Systems Inc., Goleta, CA, USA) were placed around the cavernous nerve. The stimulation parameters were as follows: 5 V at a frequency of 12 Hz, a pulse width of 1 ms, and a duration of 1 min. The maximal intracavernous pressure (ICP) was recorded during tumescence. The total ICP was determined by the area under the curve from the beginning of cavernous nerve stimulation to a point 20 s after stimulus termination. Systemic blood pressure was measured using a noninvasive tail-cuff system (Visitech Systems, Apex, NC, USA) before performing ICP determination. The ratios of maximal ICP and total ICP (area under the curve) to mean systolic blood pressure (MSBP) were calculated to adjust for variations in systemic blood pressure as previously described.
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Mouse major pelvic ganglion neurite-sprouting assay Mouse major pelvic ganglion (MPG) tissues were prepared and maintained as described previously. 25, 26 Briefly, the MPG tissues were isolated from mice in each group using a microscope (Olympus Stereo Microscope, Tokyo, Japan), transferred into sterile vials containing Hank's balanced salt solution (GIBCO), and then rinsed and washed twice in PBS. The MPG tissues were cut into small pieces, and the samples were plated on poly-D-lysine hydrobromide (Sigma-Aldrich)-coated 12-well plates. The MPG tissues were completely covered with Matrigel matrix (Corning), and the culture plate was placed on ice for 5 min and then incubated at 37°C for 10-15 min in 5% CO 2 atmosphere. Complete Neurobasal™ medium (1 ml, GIBCO) supplemented with 2% serum-free B-27 (GIBCO) and 0.5 nmol l −1 GlutaMAX-I (GIBCO) was then added. The dishes were then incubated at 37°C in 5% CO 2 atmosphere. After 3 days of incubation, we evaluated neurite outgrowth against neurofilament (Sigma-Aldrich; 1:100) and mouse tetramethyl rhodamine isothiocyanate (TRITC)-conjugated secondary antibodies (Zymed Laboratories, San Francisco, CA, USA; 1:200).
Western blot
Equal amounts of protein (50 µg per lane) were electrophoresed on sodium dodecyl sulfate-polyacrylamide gels (8%-12%, Sigma-Aldrich), transferred to nitrocellulose membranes, and probed with antibodies against phospho-endothelial nitric oxide synthase (eNOS) (Ser1177, Cell Signaling; 1:500), eNOS (Becton Dickinson; 1:500), cleaved caspase-3 (Asp175, Cell Signaling, Beverly, MA, USA; 1:500), claudin-5 (Thermo Fisher Scientific; 1:500), or β-actin (Abcam, Cambridge, UK; 1:6000). The results were quantified by densitometry at n = 4 per group (ImageJ 1.34, National Institutes of Health, Bethesda, MD, USA).
Histological examinations
For fluorescence microscopy, the penis tissue sections (12-µm thick) were fixed in 4% paraformaldehyde for 24 h at 4°C, and frozen tissue sections were incubated with antibodies against CD31 (Chemicon, Temecula, CA, USA; 1:50), PDGFR-β (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:100), phosphohistone H3 (Abcam; 1:50), cleaved caspase-3 (Asp175, Cell Signaling; 1:50), phospho-eNOS (Ser1177, Cell Signaling; 1:1000), claudin-5 (Thermo Fisher Scientific; 1:100), oxidized low density lipoprotein (LDL; Abcam; 1:400), neurofilament (Sigma-Aldrich; 1:100), or nNOS (Santa Cruz Biotechnology; 1:100) at 4°C overnight. After several washes with PBS, the sections were incubated with tetramethyl rhodamine isothiocyanate (TRITC)-conjugated (Zymed Laboratories) or FITC-conjugated secondary antibodies (Molecular Probes, Inc., Waltham, MA, USA) for 2 h at room temperature. Samples were mounted in a solution containing 4,6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Inc., CA, USA) for nuclei staining. Signals were visualized, and digital images were obtained with a confocal microscope using standard and high magnification (×100, ×200, ×400, ×800; Leica DMI4000B; Leica Microsystems, Heidelberg, Germany).
All digital image quantitative analyses and western blot band densitometry analyses were done with an image analyzer system (ImageJ 1.34, National Institutes of Health).
Statistical analysis
The results are expressed as the mean ± standard deviation (s.d.). Statistical analysis was performed using one-way ANOVA followed by Newman-Keuls post hoc test. P < 0.05 was considered statistically significant. Statistical analyses were performed using SigmaStat 3.11 software (Systat Software Inc., San Jose, CA, USA).
RESULTS
Metabolic variables
Fasting and postprandial blood glucose concentrations were higher in the STZ-induced diabetic mice than in the control mice. In addition, body weight was lower in the STZ-induced diabetic mice than in the controls. The body weight and blood glucose levels of the diabetic mice did not differ regardless of the treatment given (Supplementary Table 1 and 2).
Combination therapy with SVF and Ad-COMP-Ang1 gene restores more durable erectile function in STZ-induced diabetic mice
A representative intracavernous tracing after stimulation of the cavernous nerve (5 V, 12 Hz, and 1 ms) for 1 min in each group 2 and 4 weeks after treatment is shown in Figure 1a Table 1 and 2).
Cavernous endothelial cell and pericyte numbers are improved by combination therapy in STZ-induced diabetic mice
Immunohistochemical staining of cavernous tissue with antibodies against CD31 and PDGFR-β was performed in age-matched control and diabetic mice 4 weeks after treatment. Notably, lower cavernous endothelial cell and pericyte numbers were found in the PBS or ad-LacZ-treated diabetic mice than in the control mice. Intracavernous injection of SVF (1 × 10 5 cells per 20 µl) or Ad-COMP-Ang1 gene (2 × 10 8 particles per 20 µl) partially restored cavernous endothelial cell and pericyte numbers. Moreover, the combination treatment notably restored cavernous endothelial cell and pericyte numbers, but not to the level of the control group (all P < 0.05; Figure 2 ).
Combination therapy restores cavernous endothelial cell numbers through an increase in proliferation and a decrease in apoptosis
To determine if the increase in cavernous endothelial cell number was the result of endothelial cell proliferation, we assessed the number of endothelial cells and pericytes staining positive for phosphohistone H3 (a nuclear protein indicative of cell proliferation). Significant decreases were found in phosphohistone H3-positive endothelial cells in the PBS-and ad-LacZ-treated diabetic mice compared to the control mice. Figure 2a and 2b) .
Cavernous nNOS and neurofilament content are induced by combination therapy in STZ-induced diabetic mice
The expression of nNOS-containing nerve fiber (cavernosum) and axonal contents (neurofilament in dorsal nerve bundle) was evaluated by immunohistochemical staining in age-matched control and diabetic mice 4 weeks after treatment. The expression of nNOS and neurofilament was lower in the PBS-and ad-LacZ-treated diabetic mice than in the control mice. Intracavernous injection of SVF (1 × 10 5 cells per 20 µl) or Ad-COMP-Ang1 gene (2 × 10 8 particles per 20 µl) as single agents only partially increased nNOS expression, whereas the combination treatment completely restored nNOS (Figure 6a and 6d) expression to the level of the control group. However, only a partial effect was observed in neurofilament (Figure 6b and 6e) regeneration (P < 0.05).
Combination therapy enhances neurite sprouting in an ex vivo major pelvic ganglion tissue culture in STZ-induced diabetic mice
To test the neurotrophic effects of SVF and Ad-COMP-Ang1 gene combination therapy, we isolated and cultivated mouse major pelvic ganglion (MPG) in Matrigel matrix from age-matched control and diabetic mice 4 weeks after treatment. Immunohistochemical staining of MPG with antibodies against neurofilament showed that the neurite sprouting from MPG tissue was markedly lower in the PBS-or ad-LacZ-treated diabetic group than in the control group. * P < 0.001, P or L versus C group. # P < 0.001, S or CA versus P or L groups. † P < 0.05, S + CA versus S or CA groups. (f) Quantification of neurite length by ImageJ. Each bar depicts the mean values ±standard deviations from n = 4 animals per group.
* P < 0.001, P or L versus C group. # P < 0.001, S or CA versus P or L groups. † P < 0.001, S + CA versus S or CA groups. The P values were determined by one-way ANOVA. Ad-COMP-Ang1: adenovirus-mediated cartilage oligomeric matrix angiopoietin-1; DAPI: 4',6-diamidino-2-phenylindole; PBS: phosphate-buffered saline; nNOS: neuronal nitric oxide synthase; STZ: streptozotocin; SVF: stromal vascular fraction; MPG: major pelvic ganglion. 
DISCUSSION
Our previous study showed that freshly isolated SVF is also used for the treatment of radical prostatectomy-induced ED and diabetic ED. 12, 27 In addition, the Ad-COMP-Ang1 gene successfully restores the endogenous NO-cGMP pathway and inhibition of endothelial cell apoptosis. These changes restore erectile function for 2 weeks (90%) and 4 weeks (79%) in mice with STZ-induced diabetes. 14, 15 Furthermore, the COMP-Ang1 gene rescues erectile function and cavernous blood flow up to 8 weeks after treatment in a hypercholesterolemic mouse model, but cavernous endothelial cell number recovery is only detected at 2 weeks. 28 However, both SVF and COMP-Ang1 gene can restore erectile function at 2 weeks in a severe endothelial dysfunction and neurodegeneration model, such as STZ-induced diabetic mice. Based on these observations, we hypothesized that combination therapy with SVF and Ad-COMP-Ang1 gene may significantly improve the dual angiogenic and neurotrophic effects, which may restore more durable erectile function.
Our study showed that SVF or Ad-COMP-Ang1 gene alone restored erectile function up to 80% (maximal ICP) after 4 weeks of treatment, whereas combination therapy restored erectile function to more than 88% (maximal ICP) of control values. Our previous studies have shown that treatment with SVF and COMP-Ang1 gene induces cavernous endothelial cell numbers, eNOS phosphorylation, and endothelial cell-cell junctions but decreases cavernous endothelial cell permeability in STZ-induced diabetic mice. 12, 14 The combination therapy of these agents further enhanced these factors in STZ-induced diabetic mice for at least 4 weeks. Immunohistochemical examination of phosphohistone H3 and cleaved caspase-3 expression revealed that the increased cavernous endothelial cell and pericyte numbers resulted from endothelial cell and pericyte survival. Our previous studies have also shown that pericyte restoration induces recovery of erectile function 2 by tightly regulating vascular endothelial permeability. These findings suggest that pericyte survival may be a key mechanism in the long-term effect of an erection. However, the exact mechanisms of SVF and Ad-COMP-Ang1 gene combination in the regulation of the expression of pericytes remain unclear.
Previous studies have shown that the amount of intact neurofilament-positive axonal and nNOS-containing nerve fibers is critical for maintaining erectile function. 29, 30 In agreement with this finding, we found that combination therapy notably restored neurofilament-positive axonal and nNOS-containing nerve fibers and induced eNOS phosphorylation in the penises of STZ-induced diabetic mice. We further isolated mouse MPG and performed an ex vivo culture from conditioned mice. A severe impairment in neurite outgrowth in MPG tissue from diabetic mice was found. However, MPG neurite sprouting from the combination therapy group was profoundly enhanced compared with the groups treated with a single intracavernous injection of SVF or Ad-COMP-Ang1 gene. Previous studies have shown that SVF is a source of various angiogenic factors, such as Ang1, VEGF-A, and HGF. 16, 20, 21 Moreover, the Ang1-Tie2 signaling pathway regulates the expression of neurotrophic factors. 9 Thus, these findings suggest that the SVF and Ad-COMP-Ang1 gene combination may recover dual angiogenic and neurotrophic effects, which may induce long-term recovery of erectile function.
Although it has been reported that a single intracavernous injection of SVF or Ad-COMP-Ang1 gene may restore erectile function for 2 weeks, this is the first report showing that combination therapy with SVF and Ad-COMP-Ang1 gene may be useful for restoring more lasting erectile function up to 88% of control values for at least 4 weeks in STZ-induced diabetic mice. The dual angiogenic and neurotrophic effects of combination therapy may afford these changes.
Our study had some limitations. This study did not elucidate the detailed mechanisms by which the combination therapy regulates the dual angiogenic and neurotrophic effects. Second, a longer duration of recovery of erectile function should be tested in the combination therapy group, such as 6 or 8 weeks after treatment of STZ-induced diabetic mice.
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